The European Medicines Agency’s (EMA) safety committee (PRAC) is assessing further data on the risk of myocarditis and pericarditis following vaccination with mRNA COVID-19 vaccines.
Vaccines being reviewed are Comirnaty and Spikevax, which are manufactured by the collaboration of Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), and Moderna (Nasdaq: MRNA), respectively.
Myocarditis and pericarditis are inflammatory conditions of the heart. Symptoms can vary but often include breathlessness, a forceful heartbeat that may be irregular, and chest pain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze